The application of circulating @entity5 DNA(ctDNA) represents a non-invasive method for @entity5 detection. Its prognostic significance in @entity1 with @entity14 is controversial. We performed a systematic review of data from published studies to assess the prognostic values of ctDNA in @entity1 with @entity14 . We searched Medline, Embase, Web of Science, the Cochrane Library, and Scopus databases to identify eligible studies reporting disease-free survival (DFS) and @entity1349 ( @entity1349 ) stratified by ctDNA prior to December 6, 2016. We evaluated the quality and design of these studies. A total of 22 studies were eligible for systematic review. Among them, 11 studies investigated the prognostic value of ctDNA on disease-free survival (DFS). Seven of 11 studies showed that ctDNA was an independent variable to estimate the probability of DFS by multivariate analyses. Thirteen studies assessed the relationship between ctDNA and @entity1349 ( @entity1349 ). Eight of 13 studies showed that ctDNA was an independent predictor of worse @entity1349 through the use of multivariate analyses. This analysis provides evidence that ctDNA may be a prognostic biomarker, negatively correlated with the survival of @entity1 with @entity14 .

Prognostic value of circulating XXXX DNA in @entity1 with colon cancer: Systematic review.

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity5 :: (MESH:D009369,Disease) :: ['tumor']
